Antioxidant properties of HDL

Soran, Handrean; Schofield, Jonathan; Durrington, Paul N.

doi:10.3389/fphar.2015.00222

Cited by 132 publications

(108 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result was also confirmed in our study in isolated HDL lipoprotein fractions and suggested reduced antioxidant potential of HDL particles in renal disease . Given that free SH‐groups have the potential to neutralize oxidized phospholipids and cholesterol esters, decreased PON1 in serum, as well as in isolated HDL lipoprotein fractions may lead to oxidative damage of other lipoproteins, including HDL particles . In addition, increased uremic toxins could be an additional reason for decreased PON1 concentration in renal patients due to interference with the synthesis of PON1 itself .…”

Section: Pon1 and Diseases Connected With Atherosclerosis Developmentsupporting

confidence: 87%

Paraoxonase 1 and atherosclerosis‐related diseases

et al. 2019

View full text Add to dashboard Cite

A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high‐density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti‐inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis‐related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end‐stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.

show abstract

Section: Pon1 and Diseases Connected With Atherosclerosis Developmentsupporting

confidence: 87%

Paraoxonase 1 and atherosclerosis‐related diseases

et al. 2019

View full text Add to dashboard Cite

show abstract

“…38 The HDL-binding glycoprotein PON-1 is shown to be critical for the antioxidative capacity of HDL. 42 A previously published association of low PON-1 activity and poor longterm prognosis in patients with CHF was visible in our cohort in unadjusted Cox regression analysis but turned nonsignificant after adjustment for potential confounders including implementation of HOI in our multivariable model. 17 Although we saw a significant association between PON-1 activity and the measured antioxidative capacity in the unadjusted model, this relationship was no longer observed after multivariable adjustment.…”

Section: Discussionsupporting

confidence: 49%

“…HDL particles are composed of lipids and more than 100 different proteins and exert their protective functions by the collaboration of essential apolipoproteins and associated enzymes . The HDL‐binding glycoprotein PON‐1 is shown to be critical for the antioxidative capacity of HDL . A previously published association of low PON‐1 activity and poor long‐term prognosis in patients with CHF was visible in our cohort in unadjusted Cox regression analysis but turned nonsignificant after adjustment for potential confounders including implementation of HOI in our multivariable model .…”

Section: Discussionmentioning

confidence: 59%

Impaired High‐Density Lipoprotein Anti‐Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure

Schrutka

Distelmaier

Hohensinner

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundOxidative stress is mechanistically linked to the pathogenesis of chronic heart failure (CHF). Antioxidative functions of high‐density lipoprotein (HDL) particles have been found impaired in patients with ischemic cardiomyopathy; however, the impact of antioxidative HDL capacities on clinical outcome in CHF patients is unknown. We therefore investigated the predictive value of antioxidative HDL function on mortality in a representative cohort of patients with CHF.Methods and ResultsWe prospectively enrolled 320 consecutive patients admitted to our outpatient department for heart failure and determined antioxidative HDL function using the HDL oxidative index (HOI). During a median follow‐up time of 2.8 (IQR: 1.8‐4.9) years, 88 (27.5%) patients reached the combined cardiovascular endpoint defined as the combination of death due to cardiovascular events and heart transplantation. An HOI ≥1 was significantly associated with survival free of cardiovascular events in Cox regression analysis with a hazard ratio (HR) of 2.28 (95% CI 1.48‐3.51, P<0.001). This association remained significant after comprehensive multivariable adjustment for potential confounders with an adjusted HR of 1.83 (95% CI 1.1‐2.92, P=0.012). Determination of HOI significantly enhanced risk prediction beyond that achievable with N‐terminal pro‐B‐type natriuretic peptide indicated by improvements in net reclassification index (32.4%, P=0.009) and integrated discrimination improvement (1.4%, P=0.04).ConclusionsImpaired antioxidative HDL function represents a strong and independent predictor of mortality in patients with CHF. Implementation of HOI leads to a substantial improvement of risk prediction in patients with CHF.

show abstract

“…Measurement of PON1 activity is an accepted indicator of the HDL antioxidant property and a promising biomarker of HDL function independently of HDL-C levels [20] . PON1 inhibits lipoprotein oxidation and macrophage foam cell formation.…”

Section: Discussionmentioning

confidence: 99%

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Harangi¹,

Szentpéteri²,

Nádró³

et al. 2017

View full text Add to dashboard Cite

Aim:The protective role of high-density lipoprotein (HDL) against atherosclerosis is well known. However, both structural and functional changes of the HDL particles may affect its protective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreased HDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Some changes in HDL subfraction distributions were also studied previously, but data on structural and functional changes in dyslipidemia are not complete. Therefore, the authors aimed to evaluate these qualitative and quantitative markers of HDL in dyslipidemic patients and healthy control subjects. Methods: Anthropometric parameters, serum levels of lipoproteins and MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patients and in 32 healthy gender-matched controls. Additionally, HDL subfractions were detected by an electrophoretic method on polyacrylamide gel (Lipoprint). Results: Significantly higher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol, triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were found in patients compared to the healthy subjects. There were no significant differences in PON1 paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratio was significantly higher in patients. There was a shift towards the smaller HDL subfractions, but only the intermediate HDL ratio was significantly lower in patients compared to controls. Conclusion:The results highlight the importance of HDL-associated pro-and antioxidant enzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm that quantification of HDL-C level alone provides limited data regarding HDL's cardioprotective effect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia. Key words:High-density lipoprotein, subfraction, paraoxonase, myeloperoxidase, dyslipidemia ABSTRACTArticle history:

show abstract

Antioxidant properties of HDL

Cited by 132 publications

References 52 publications

Paraoxonase 1 and atherosclerosis‐related diseases

Paraoxonase 1 and atherosclerosis‐related diseases

Impaired High‐Density Lipoprotein Anti‐Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Contact Info

Product

Resources

About